![](https://endpts.com/wp-content/uploads/2022/07/GettyImages-1193473360-scaled.jpg)
Bill Anderson, Roche pharma chief (David Paul Morris/Bloomberg via Getty Images)
Roche trims out some pipeline failures while flagging a PhIII flop for Tecentriq
Roche flagged a key setback for its late-stage pipeline today, saying their IMmotion010 kidney cancer adjuvant study of Tecentriq has failed.
Roche pharma chief Bill …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.